Company Profile
Meditrina Pharmaceuticals, Inc.
Reproductive
Drug Development
300 N. Fifth Ave
Suite 150
Ann Arbor, MI 48104
USA
www.meditrina.com
|
Incorporated in 2006
6 Employees
|
Privately Held
|
|
This Year's Highlights
- Opened first IND and completed enrollment for Phase 2 trial
- Recruited complete management team (6 senior team members): CEO, COO/VP Business Development (ex-Searle), VP Clincial Development (ex-Pfizer), Chief Medical Officer (ex-Pfizer), CFO, Senior Director Manufacturing/Quality (ex-Pfizer)
- Raised $4.4 million in start-up funding under favorable terms
|
Anticipated Highlights
- Complete Phase 2 timing/scheduling trial to demonstrate that estradiol can be reduced at any time in a woman's cycle. Initiate pivotal Phase 3 trial in 2008
- Open IND for second indication (endometriosis and/or ectopic pregnancy) in 2007 and initiate clinical trial(s) in Q1 2008
- Close Series A financing of $5 million to $20 million (tranched)
|
|
Corporate Mission
Meditrina Pharmaceuticals is a specialty pharmaceutical company dedicated to bringing to market new medicines to improve women?s health
|
